Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers DOI Creative Commons
Jianan Jin, Haibo Mou, Yibin Zhou

et al.

Cancer Control, Journal Year: 2024, Volume and Issue: 31

Published: Jan. 1, 2024

Background Immune therapy, especially involving PD-1/PD-L1 inhibitors, has shown promise as a therapeutic option for cholangiocarcinoma. However, limited studies have evaluated survival outcomes in cholangiocarcinoma patients treated with immune therapy. This study aims to develop predictive model evaluate the benefits of therapy Methods retrospective analysis included 120 from Shulan (Hangzhou) Hospital. Univariate and multivariate Cox regression analyses were conducted identify factors associated following A was constructed validated using calibration curves (CC), decision curve (DCA), concordance index (C-index), receiver operating characteristic (ROC) curves. Results identified several potential predictors post-immune cholangiocarcinoma: treatment cycle (<6 vs ≥ 6 months, 95% CI: 0.119-0.586, P = 0.001), neutrophil-to-lymphocyte ratio (NLR <3.08 3.08, 1.864-9.624, carcinoembryonic antigen (CEA <4.13 4.13, 1.175-5.321, 0.017), presence bone metastasis (95% 1.306-6.848, 0.010). The nomogram achieved good accuracy C-index 0.811. CC indicated strong between predicted observed outcomes. Multi-timepoint ROC at 1, 2, 3 years model’s performance (1-year AUC: 0.906, 2-year 0.832, 3-year 0.822). multi-timepoint DCA also demonstrated higher net benefit compared extreme Conclusion model, incorporating key risk demonstrates robust outcomes, offering improved clinical decision-making.

Language: Английский

Non-invasive PD-L1 stratification in non-small cell lung cancer using dynamic contrast-enhanced MRI DOI Creative Commons
Gaia Messana, Chandra Bortolotto, Sithin Thulasi Seetha

et al.

European Radiology, Journal Year: 2025, Volume and Issue: unknown

Published: March 27, 2025

Abstract Objectives This study aimed to assess whether pharmacokinetic parameters derived from DCE-MRI can stratify Programmed Death-Ligand 1 (PD-L1) expression in NSCLC. The secondary aim was identify a suitable model configuration for anisotropic temporally-spaced sequences, considering Tofts variants, population-averaged arterial input functions (AIF), and bolus arrival time (BAT) estimation methods. Materials methods From April 2021 May 2023, patients with locally advanced non-small cell lung cancer (NSCLC) were prospectively enrolled. Tumors categorized based on: PD-L1 absence/presence (threshold 1%) hyperexpression/hypoexpression 50%). Pharmacokinetic extracted using several candidate configurations; fit quality evaluated coefficient of determination ( R ²). Mann–Whitney U-test ROC-AUC used correlation the best-fit configuration. Results Thirty-eight (mean age 68 ± 9 years, 28 men) included. present 25 (66%) absent 13 (34%). hyperexpressed (34%) hypoexpressed (66%). Voxel-wise configuration—extended (ETM) Georgiou AIF Peak-Gradient (PG) BAT 2 = 0.79). K trans median (0.25 vs. 0.12 min − ¹, p 0.02), standard deviation (0.32 0.23 0.01) ep (1.09 0.59 0.02) significantly higher < 50% group (ROC-AUC 0.71–0.76). Conclusion could hypo/hyperexpression ETM PG method best-performing Key Points Question Could Dynamic Contrast-Enhanced (DCE) MRI offer safe non-invasive way expression? Findings Quantitative (the volume transfer rate) efflux rate constant) show potential distinguishing hyperexpression hypoexpression. Clinical relevance Preliminary results suggest that be cancer, potentially optimizing treatment decisions, given high cost immunotherapy. Graphical

Language: Английский

Citations

0

Concurrent vs. sequential chemoradiotherapy: a survival boost for lung cancer patients DOI Creative Commons
Jin‐Biao Xu, Qiao Ji, Jianxiong Deng

et al.

BioMedical Engineering OnLine, Journal Year: 2025, Volume and Issue: 24(1)

Published: May 16, 2025

To investigate the clinical efficacy, incidence of radiation pneumonitis, and impact on lung function sequential chemoradiotherapy (SCRT) concurrent (CCRT) in treatment cancer. From January 2020 to December 2022, 158 patients with non-small cell cancer (NSCLC) were admitted our hospital chosen as study subjects. Their data analyzed retrospectively organized into a control group (n = 78, received SCRT) an observation 80, CCRT). Lesion sizes measured through CT scans used compare efficacy between two groups. The also compared rates adverse reactions, pre- post-treatment, including forced expiratory volume one second (FEV1), vital capacity (FVC), FEV1/FVC ratio. comparison serum tumor marker levels was conducted groups, being observed over 36-month period. Kaplan-Meier survival curves analyze changes overall rate (OSR), progression-free (PFS), (OS) groups patients. For group, remission 90.00%, for it 74.36%. 96.25% 89.74% group. Significantly higher than (P < 0.05). hemoglobin reduction grade 0 81.2% 58.9% In terms leukopenia (grades 0-III) 0-II), outperformed 25.00% experienced 8.97% Overall, more severe radiation-induced injury 6.41% cases reaching IV, unlike 0.00% Grade II accounted 1.28% figure significantly lower 21.25% Post-treatment, FEV1, FVC, values rose both displaying greater increases Also, after treatment, there decrease CA125, SCC Ag, CYFRA21-1 having According curve analysis, achieved OSR which exceeded 83.33% > Furthermore, PFS OS elevated relative CCRT could optimize effect NSCLC by improving function, reducing levels, prolonging without increasing toxicity. Nonetheless, occurrence pneumonitis somewhat above expectations, plan should be tailored patient's specific circumstances practice.

Language: Английский

Citations

0

Nomogram for Predicting Survival Post-Immune Therapy in Cholangiocarcinoma Based on Inflammatory Biomarkers DOI Creative Commons
Jianan Jin, Haibo Mou, Yibin Zhou

et al.

Cancer Control, Journal Year: 2024, Volume and Issue: 31

Published: Jan. 1, 2024

Background Immune therapy, especially involving PD-1/PD-L1 inhibitors, has shown promise as a therapeutic option for cholangiocarcinoma. However, limited studies have evaluated survival outcomes in cholangiocarcinoma patients treated with immune therapy. This study aims to develop predictive model evaluate the benefits of therapy Methods retrospective analysis included 120 from Shulan (Hangzhou) Hospital. Univariate and multivariate Cox regression analyses were conducted identify factors associated following A was constructed validated using calibration curves (CC), decision curve (DCA), concordance index (C-index), receiver operating characteristic (ROC) curves. Results identified several potential predictors post-immune cholangiocarcinoma: treatment cycle (<6 vs ≥ 6 months, 95% CI: 0.119-0.586, P = 0.001), neutrophil-to-lymphocyte ratio (NLR <3.08 3.08, 1.864-9.624, carcinoembryonic antigen (CEA <4.13 4.13, 1.175-5.321, 0.017), presence bone metastasis (95% 1.306-6.848, 0.010). The nomogram achieved good accuracy C-index 0.811. CC indicated strong between predicted observed outcomes. Multi-timepoint ROC at 1, 2, 3 years model’s performance (1-year AUC: 0.906, 2-year 0.832, 3-year 0.822). multi-timepoint DCA also demonstrated higher net benefit compared extreme Conclusion model, incorporating key risk demonstrates robust outcomes, offering improved clinical decision-making.

Language: Английский

Citations

2